Previous 10 | Next 10 |
Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into Q1 2025 Phase 2 Photoparoxsymal Response (PPR) study to evaluate PRAX-628 expected to read-out by YE 2023 Plan to begin ulixacaltamide...
2023-06-16 05:59:42 ET Praxis Precision Medicines ( NASDAQ: PRAX ) shares fell 6.15% premarket on Friday after the biopharma company priced its securities offering to raise around $59.1M in gross proceeds. The offering comprises 55.15M ordinary share...
BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...
2023-06-15 16:25:12 ET Praxis Precision Medicines ( NASDAQ: PRAX ) said Thursday it plans to conduct a public offering of its common stock. All shares in the offering will be offered by the company. The underwriters are expected to have a 30-day option to purchase up to an...
BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...
2023-06-09 13:01:49 ET Praxis Precision Medicines ( NASDAQ: PRAX ) added ~4% on Friday after announcing results from an end-of-Phase 2 meeting with the FDA regarding plans to advance its lead candidate ulixacaltamide for Phase 3 development in movement disorder, Essential Tremor...
Phase 3 program to include one parallel group study and one randomized withdrawal study mADL11 as primary endpoint Single 60 mg/day dose to be tested BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmac...
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...
2023-05-11 14:05:09 ET Praxis Precision Medicines press release ( NASDAQ: PRAX ): Q1 GAAP EPS of -$0.71. Revenue of $0.68M. For further details see: Praxis Precision Medicines GAAP EPS of -$0.71, revenue of $0.68M
2023-05-11 09:29:59 ET More economic data, earnings reports, performance outlooks from management teams, and the Federal Reserve are driving sentiment in the stock market today. Whether you’re trading penny stocks or higher-priced company shares, there’s no getting around ...
News, Short Squeeze, Breakout and More Instantly...
Praxis Precision Medicines Inc. Company Name:
PRAX Stock Symbol:
NASDAQ Market:
Praxis Precision Medicines Inc. Website:
2024-07-26 13:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 13:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-20 14:30:05 ET Piper Sandler analyst issues OVERWEIGHT recommendation for PRAX on May 20, 2024 12:01PM ET. The previous analyst recommendation was Overweight. PRAX was trading at $44.93 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...